双柏散外敷联合吗啡对肝癌中重度癌痛的增效减毒作用
|
摘要
目的
通过加味双柏散(简称双柏散)局部外敷联合吗啡对肝癌中重度疼痛的临床疗效及生存质量的观察,为肝癌患者寻求一种有效、安全、经济、耐受性好的癌痛辅助治疗药物。
方法
通过随机、双盲、对照、多中心的临床研究,将34例原发性肝癌合并肝区中重度疼痛的患者作为研究对象,随机分为治疗组17例,对照组17例,分别予双柏散或安慰剂局部外敷疼痛处,连续治疗7天,并指导患者进行NRS评分及生存质量评分(《QLQ-C30生存质量》)。通过比较患者治疗前后NRS及生存质量评分,以观察双柏散联合吗啡治疗肝癌中重度疼痛的临床疗效及生存质量的影响。
结果
在NRS评分方面,经治疗后,治疗组NRS评分下降幅度较显著,与对照组相应时点的评分进行比较,差别具有统计学意义(P<0.05)。在开始敷药后3小时内疗效最佳,另随着治疗时间的推移,治疗组下降的趋势与对照组不一致。提示双柏散不仅有较好的止痛效果,同时有疗效维持的趋势,符合中药外敷疗效持久的特点。
在止痛药使用方面,治疗组使用的美施康定人均用量低于对照组。在治疗过程中,在爆发性疼痛的次数方面,治疗组和对照组无明显差异,具有统计学意义(P<0.05)。提示双柏散外敷联合吗啡可以减少止痛药物的用量。
在生存质量评分方面,经过治疗后,治疗组与对照组在恶心与呕吐、腹泻、便秘、食欲丧失、疲倦、疼痛等均有显著性差异(P<0.05),治疗组在评价生存质量的上述领域方面优于对照组,提示双柏散可减轻患者的消化道反应。
在KPS评分方面,随着治疗时间的推移,两组间KPS变化趋势不一致,具有统计学意义(P<0.05)。提示经治疗,治疗组的KPS高于对照组。
安全性方面,治疗后,两组患者在血分析、肝肾功能无统计学意义(P>0.05),提示双柏散外敷肝区痛处对造血系统及肝肾功能无不良作用。一般体检项目未见异常。部分患者在外敷药物时出现痉痒、水疱等不适,两组在不良反应方面无统计学差异(P>0.05),所有出现不适的患者症状均较轻,未见不良反应而退出实验者。
结论
双柏散局部外敷联合吗啡治疗肝癌中重度癌痛起到较好的止痛效果。通过降低止痛药的用量,在一定程度减少吗啡药物引起的恶心呕吐、纳差、便秘、疲倦等消化道症状,提高肝癌患者的生存质量,起到增效减毒的作用。其副作用小,简单易行。双柏散联合吗啡是治疗肝癌中重度癌痛一种有效、安全、经济的治疗手段。
Objective
The objective of this study was to observe the clinical therapeutic efficacy and the quality of Life using shuang Baisan on relieving Pain and improving the quality of life of the primary liver cancer patients with the moderate and severe pain. to observe an effective, safe, economical and assistant medication in treating the cancer Pain.
Methods
34eligible Patients, having the moderate and severe pain of liver or upper abdominal, were divided into the treatment group (17patients) and and control group(17patients) in a double-blind, randomized, controlled,multi-center study. All patients were received7days treatment of ShuangBaisan(in treatment group)or placebo (in control group) by external application. Guided the patients to fill the NRS score and 《quality of life instruments QLQ-C30V3.0》, made an analysis of the score changes of NRS and quality of life after the treatment, then evaluated the effect of Shuang Baisan on relieving pain and improving the quality of life of the patients with primary liver cancer
Results
After therapy, The NRS scores in the treated had showed a significant decreasing trend compared with those in control group in the corresponding (P<0.05), prompting the clinical effect in the treatment group were superior to that in the control group, and the best effect was the three hours after the start of the treatmen.Over time both of the downward trend was inconsistent which suggested that Shuang Baisan had a persistent effect in relieving pain.
During the course of therapy, research group using average morphine was well bejow the corntoJ. Break pain of the both group patients had no significant diiference (P>0.05),which suggested that Shuang Baisa combined with morphine can reduce the amount of morphine.
After therapy, the result in the quality of life showed that Patients in the treatment group had a better living quality in nausea and vomiting, constipation, diarrhea, appetite loss, languor etc than in the control group (P＜0.05), which suggested that Shuang Baisa can alleviate digestive tract reaction.
in terms of KPS, Over time t he KPS in the treated had showed a signi ficant upwards trend compared with those in control group. The difference we staiistically significant(P<0.05).
At the safety aspect, from data analysis of change for complete blood count and hepatic/renal function, None of these had adverse reactions
Conclusion
Shuang Baisan had better effeet. on relieving pain combined with morphine in the primary liver cancer patients with the moderate and severe pain.lt could alleviate digestive tract reaction.of nausea and vomiting, constipation, diarrhea, appetile loss, languor etc due to reduce the dosage of morphine, it could improve the quality of life of the Patients, possessed the effect of improving the efficiency and depressing the toxicity. It had less side effeet and simple.These suggested shuang Baisan had better effeet on relieving pain combined with morphine. It would be an effective, safe and economical assistant medication for liver cancer pain.
通过加味双柏散(简称双柏散)局部外敷联合吗啡对肝癌中重度疼痛的临床疗效及生存质量的观察,为肝癌患者寻求一种有效、安全、经济、耐受性好的癌痛辅助治疗药物。
方法
通过随机、双盲、对照、多中心的临床研究,将34例原发性肝癌合并肝区中重度疼痛的患者作为研究对象,随机分为治疗组17例,对照组17例,分别予双柏散或安慰剂局部外敷疼痛处,连续治疗7天,并指导患者进行NRS评分及生存质量评分(《QLQ-C30生存质量》)。通过比较患者治疗前后NRS及生存质量评分,以观察双柏散联合吗啡治疗肝癌中重度疼痛的临床疗效及生存质量的影响。
结果
在NRS评分方面,经治疗后,治疗组NRS评分下降幅度较显著,与对照组相应时点的评分进行比较,差别具有统计学意义(P<0.05)。在开始敷药后3小时内疗效最佳,另随着治疗时间的推移,治疗组下降的趋势与对照组不一致。提示双柏散不仅有较好的止痛效果,同时有疗效维持的趋势,符合中药外敷疗效持久的特点。
在止痛药使用方面,治疗组使用的美施康定人均用量低于对照组。在治疗过程中,在爆发性疼痛的次数方面,治疗组和对照组无明显差异,具有统计学意义(P<0.05)。提示双柏散外敷联合吗啡可以减少止痛药物的用量。
在生存质量评分方面,经过治疗后,治疗组与对照组在恶心与呕吐、腹泻、便秘、食欲丧失、疲倦、疼痛等均有显著性差异(P<0.05),治疗组在评价生存质量的上述领域方面优于对照组,提示双柏散可减轻患者的消化道反应。
在KPS评分方面,随着治疗时间的推移,两组间KPS变化趋势不一致,具有统计学意义(P<0.05)。提示经治疗,治疗组的KPS高于对照组。
安全性方面,治疗后,两组患者在血分析、肝肾功能无统计学意义(P>0.05),提示双柏散外敷肝区痛处对造血系统及肝肾功能无不良作用。一般体检项目未见异常。部分患者在外敷药物时出现痉痒、水疱等不适,两组在不良反应方面无统计学差异(P>0.05),所有出现不适的患者症状均较轻,未见不良反应而退出实验者。
结论
双柏散局部外敷联合吗啡治疗肝癌中重度癌痛起到较好的止痛效果。通过降低止痛药的用量,在一定程度减少吗啡药物引起的恶心呕吐、纳差、便秘、疲倦等消化道症状,提高肝癌患者的生存质量,起到增效减毒的作用。其副作用小,简单易行。双柏散联合吗啡是治疗肝癌中重度癌痛一种有效、安全、经济的治疗手段。
Objective
The objective of this study was to observe the clinical therapeutic efficacy and the quality of Life using shuang Baisan on relieving Pain and improving the quality of life of the primary liver cancer patients with the moderate and severe pain. to observe an effective, safe, economical and assistant medication in treating the cancer Pain.
Methods
34eligible Patients, having the moderate and severe pain of liver or upper abdominal, were divided into the treatment group (17patients) and and control group(17patients) in a double-blind, randomized, controlled,multi-center study. All patients were received7days treatment of ShuangBaisan(in treatment group)or placebo (in control group) by external application. Guided the patients to fill the NRS score and 《quality of life instruments QLQ-C30V3.0》, made an analysis of the score changes of NRS and quality of life after the treatment, then evaluated the effect of Shuang Baisan on relieving pain and improving the quality of life of the patients with primary liver cancer
Results
After therapy, The NRS scores in the treated had showed a significant decreasing trend compared with those in control group in the corresponding (P<0.05), prompting the clinical effect in the treatment group were superior to that in the control group, and the best effect was the three hours after the start of the treatmen.Over time both of the downward trend was inconsistent which suggested that Shuang Baisan had a persistent effect in relieving pain.
During the course of therapy, research group using average morphine was well bejow the corntoJ. Break pain of the both group patients had no significant diiference (P>0.05),which suggested that Shuang Baisa combined with morphine can reduce the amount of morphine.
After therapy, the result in the quality of life showed that Patients in the treatment group had a better living quality in nausea and vomiting, constipation, diarrhea, appetite loss, languor etc than in the control group (P＜0.05), which suggested that Shuang Baisa can alleviate digestive tract reaction.
in terms of KPS, Over time t he KPS in the treated had showed a signi ficant upwards trend compared with those in control group. The difference we staiistically significant(P<0.05).
At the safety aspect, from data analysis of change for complete blood count and hepatic/renal function, None of these had adverse reactions
Conclusion
Shuang Baisan had better effeet. on relieving pain combined with morphine in the primary liver cancer patients with the moderate and severe pain.lt could alleviate digestive tract reaction.of nausea and vomiting, constipation, diarrhea, appetile loss, languor etc due to reduce the dosage of morphine, it could improve the quality of life of the Patients, possessed the effect of improving the efficiency and depressing the toxicity. It had less side effeet and simple.These suggested shuang Baisan had better effeet on relieving pain combined with morphine. It would be an effective, safe and economical assistant medication for liver cancer pain.
引文
[1]孙燕,石远凯.临床肿瘤内科手册[R].北京：大民卫生出版社,2007.9
[2]Goldstein FJ. Adjuncts to opioid therapy[J].J Am Osteopath Assoc,2002,102 (9):S152S21.
[3]周之毅,刘慧.癌性疼痛的中医药质量进展[J].辽宁中医杂志,2007,34(4)：534-536.
[4]白桦,李忠,张雅月.中药外用缓解癌性疼痛的研究现状与思路[J].中医外治志,2009,18(1)：46-48.
[5]Parkin DM,Bray F, Ferlay J,et al.Global cancer statistics[J].CA Cancer J Clin,2005,55(2):74-108.
[6]Summerfield JA. Virus hepatitis update[J]. J R Coll Physicians Lond,2000,34(4): 381-385
[7]丁凯,周华富,冯志强.原发性肝癌的病因研究与进展[J].中国新医学论坛,2008,8(8)：21-24
[8]Hitzfeld BC, Hoger SJ, Dietrich DR. cyanobacterial toxins:removal during drinking water treatment and haman risk assessment [J]. Environ Health Perspect,2000,108(SI): 113-122
[9]董先杰,邵英梅.原发性肝癌的治疗进展,现代肿瘤医学,2009,17(09)：1814-1817
[10]Josep M, Llovet, Josep Fuster, et al. The barcelona approach:diagnosis, stag ing, and treatment of hepatocellular carcinoma[J]. Liver Transpl,2004,10:S115 S120.
[11]Lencioni R, Cioni D, Crocetti L, et a 1. Early stage hepatocellular carcinoma in patients with cir rhosis:long-term results of percutaneo us image guided radio frequency ablation[J]. Radiolo gy,2005,234(3):961-967.
[12]尹光忍,何世举.原发性肝癌的诊断及治疗现状[J].检验医学与临床2010,7(17)：1900-1901
[13]张亦琳,朱建平,叶军.肝癌的治疗方法[J].健康博览,2010,(11)：12—13.
[14]Boige V, Barbare JC, Rosmorduc 0, et al. Use of sorafenib (Nexav ar) in the t reatment of hepatocel lular carcinoma:PRODIGE AFEF recommendations [J]. Gastro errterol Clin Biol,2008,32(1 Pt 1):3-7
[15]周际吕.实用肿瘤内科学[M].北京：人民卫生出版社,2003.
[16]Honore P, Rogers SD, S chweiM J, et al M urine models of inflammatory, neuropath ic and cancer pain each generates a uniqueset of neu roch em ical ch anges in the spinal cord and sensory neurons[J]. N euroscience,2000,98(3):585-598.
[17]张瑛,韩济生,王韵.癌症痛的神经生物学机制研究进展[J].生理科学进展,2004,35(3)：224-228.
[18]Sabino MA, Luger NM, Mach DB, et al Different tumors in bone each give rise to a distinct pattern of skeletal destruction, bone cancer-related pain b ehaviors and neurochem ical changes in the centralnorvous system [J]. Int J Cancer,2003,104 (5):550 558.
[19]Manthyh PW, Clohisy DR, Kohzenbu rg M, et a.l Molecular mechanisms of cancer pain [J]. Nature Rev (Cancer),2002,2(3):201-209.
[20]王妙苗.癌瘙的发生机制及其相关药物治疗的研究现状[J].临床肿瘤学杂志,2011,16(7)：662-666
[21]Poon RT, Fan ST, Ng 10, et al. Difference risk factors and prognosis for early and late intrahepatic recurrence after resection of hepatocellular carcinoma[J]. Cancer,2000,83(3):500-507.
[22]程乐,钟进才.阿片类药物应用于中重度癌瘙治疗的研究进展[R].广西医学,2009,31(5)：742-745.
[23]徐学庆,刘雨桃,译.吗啡的新作用抑癌作用及其机制[J].日本医学介绍,2000,21(11)：522-523.
[24]Goldstein FJ. Adjuncts to opioid therapy [J].J Am Osteopath Assoc,2002,102(9):S152S21.
[25]周之毅,刘慧.癌性疼痛的中医药质量进展[J].辽宁中医杂志,2007,34(4)：534-536.
[26]刘端祺.“三阶梯”止痛原则临床实践20年[J].医学与哲学(临床决策论坛版),2007,28(10)：10-18
[27]周岱翰.临床中医肿瘤学[M].北京：人民卫生出版社,2003,1：175
[28]吴勉华.周仲瑛教授从癌毒辨治恶性肿瘤用药分析[N].南京中医药大学学报2010,26(4)
[29]赵磊.周维顺治疗肝癌经验[J].山西中医.2010,26,(12)：9-12
[30]逯敏.刘伟胜教授治疗肿瘤学术思想探讨[J].中国中医急症.2010,19(7)：1162-1163
[31]袁海英.陈培丰教授治疗肝癌经验[J].浙江中西医结合杂志.2009,19(12)
[32]吕书勤.浅析肝癌与湿[J].天津中医药,2004,21(2)
[33]吴良村,成文武,郭勇,等.中西医治疗原发性肝癌经验[J].浙江中医学院学报,2000,(4)：5
[34]苏全胜,薛利军,等.复方苦参注射液治疗老年晚期癌症患者疼痛临床体会[J]中国中医急症,2009,18(10)：1692
[35]刘安,魏静,谭镇岳.复方苦参注射液缓解癌痛的临床与实验研究[J].吉林中医药,2005,25(6)：54
[36]司富春,李建省.中医治疗癌痛证型方药分析[N].中医学报,2010-12,25(4)：
[37]王国平.清营汤加味治疗癌性疼痛68例观察[J].山西中医,1992,8(1)：25.
[38]林胜友.马钱子治疗癌性疼痛35例[J].辽宁中医杂志,1993,20(2)：41-42
[39]刘昭坤.芍药甘草汤为主治疗癌症晚期疼痛40例.新中医,1997,29(1)：29-33
[40]陈长怀,孙桂芝,唐文秀,等.桂参止痛合剂治疗癌症疼痛临床观察[J].中国新药杂志,2000,9(3)：196-200
[41]郑少翰,卓建腾.益气化瘀解毒方防治癌性疼瘙32例[J].福建中医药,2005,36(6)10-11.
[42]魏强,陈树泉,王兆香,等.酸味三君子方治疗癌性疼瘙临床观察[J].河南中医,2005,25(12)：34-34.
[43]周岱翰.临床中医肿瘤学[M].北京：人民卫生出版社,2003：70.
[44]李忠.浅述癌性疼瘙的中医论治八大法[J]. 中国临床医生,2000,28(9)：40-42.
[45]陈世伟,张利民.肿瘤中西医综合治疗.北京：人民卫生出版社,2001.195
[46]刘延庆.癌性疼痛的中医药治疗[J].江苏中医药,2008.40(9)：9.
[47]汀德家.针刺治疗癌性疼痛32例疗效观察[J].实用中医内科杂志,2007,21(9)：96-97
[48]陈仲杰,郭宇鹏. 以瘙为腧针刺治疗癌性疼痛疗效观察[J]. 中国针灸,2008,28(4)：251-252.
[49]殷常春.蟾皮止痛膏治疗癌性疼痛28例[J].中医外治杂志,2000,9(6)：10-11
[50]龚金兴,尤建良.消癥止痛膏的研制及临床疗效观察[J].中药材,2002,25(8)：611612
[51]胡怀强,李杰.癌痛膏外敷治疗肝癌疼痛46例[J].中医外治杂志,1998,7(2)：18.
[52]孙琛,唐由君.中医药外治肝癌疼痛的研究进展[J].中医外治杂志,2008,17(1)：44-46.
[53]赵玉香,赵玉玲,胡遵荣.疏络膏穴位外敷缓解癌症疼痛的临床研究[J].中医外治杂志,2003,12(2)：1
[54]韩子敏,刘兴明.中药穴区外敷治疗癌痛44例[J].中日友好医院学报,1998,12
[55]徐钧.癌瘙酊外用治疗晚期肝癌疼痛临床观察[J].现代中西医结合杂志,1999,8(7)：1076.
[56]李佑民,刘组发.冰红酊剂外用治疗肝癌疼痛42例[J].中西医结合肝病杂志,1999,9(1)：44.
[57]李敏,马岩.癌痛灵贴膏外用治疗胰腺癌癌性疼痛的疗效观察[J].华西医学,2010,25(3)：604-606
[58]李园.祛痛喷雾酊治疗癌性疼痛的临床与实验研究[J].中医杂志,1999,40(10)：609.
[59]杨劫,寇胜玲,旋志刚.元麝止痛液的制备及治疗癌性疼痛的疗效观察[J].中成药,2005,27(2)：243
[60]白桦,李忠,张雅月.中药外用缓解癌性疼痛的研究现状与思路[J].中医外治杂志,2009,18(1)： 46-48
[61]王凯,范晓鹏,林亚杰.外治法治疗肝癌癌性疼痛临床观察[J].上海中医药杂志2002,36(7)：19-20
[62]刘安,魏静,谭镇岳.中药贴脐缓解癌痛的临床与实验研究[J].云南中医中药杂志,2005,26(2)： 25-26
[63]吴迪,冯肖卿,李卫东.四黄散外敷治疗原发性肝癌疼痛临床观察[J].中材药,2010,3(37)：1197-1199.
[64]李永浩.双柏散外敷治疗肝癌疼痛疗效观察[J].中医外治杂志,2004,13(3)：26.
[65]孙韩静.冰黄寄奴散外敷治疗癌性疼痛35例疗效观察[J].新中医,2007,39(2)：84-85.
[66]王鹏,吴勉华.中医外治法在癌性疼痛中应用概述[J].实用中医内科杂志,2006,20(6)：589.
[67]郑玉玲.癌痛中医外治概况[J].光明中医杂志,1994,(1)：41-45
[68]曹海涛,张彩,徐燎宇.何裕民中医外治法治疗肿瘤经验[J].中医文献杂志,2006,(1)：36-37.
[69]杨瑶瑶,鲍艳举,花宝金.中医外治法治疗癌性疼瘙的药物分析[J].中国中医药信息杂志,2010,17(5)：94-95.
[70]邓宏,吴万垠,柴小垠.刘伟胜教授辨治癌痛经验介绍[J].新中医,2009,41(3)：15-16.
[71]何子强.肝癌疼瘙中医外治法[J].中医外治杂志,1995,(1)：27-29
[72]梁学政,吴昭璇.双柏散制剂的研究及临床应用进展.中国药业,2003,12(7)：77-78
[73]欧阳伟珊,刘东辉,魏刚.双柏散各单味药有效部位抗炎镇瘙祛瘀作用研究[J].中药药理与临床,2011,27(2)：118-121
[74]魏刚,方永奇,刘东辉.双柏散治疗作用的化学物质基础探讨[J].中药新药与临床药理,2002,13(5)：330-331
[75]方永奇,谢沙,黄可儿,等.双柏散抗炎作用及其有效部位的研究[J].广州中医学院学报,1991,8(1)：22-23
[76]吴启瑞,方永奇,黄可儿,等.双柏炎痛喷雾剂抗炎镇痛作用研究[J].中国实验方剂学杂志,1999,5(5)：49-50
[77庄洪,岑泽波,袁浩,等.外用双柏散浸剂治疗急性软组织损伤的实验研究[J].中医止骨,1992,4(2)：4-5
[78]李惠东,黄玫.双柏散在治疗创伤性肋骨骨折中的作用[J].广州医学,1998,29(4)：54-56
[79]胡继功,谢贵四.双柏散治疗骨折后软组织肿胀的疗效观察[J]贵阳中医学院学报,2011,33(4)：51-52
[80]卓晓英,罗丽英,龚博慎.双柏散外敷治疗急性软组织损伤1681例的临床观察[J].中国现代医学杂志,2006,16(5)：2389-2390
[81]郑泽棠.双柏散在外科中的应用.新中医,1992,24(4)：29
[82]张菲辉,李惠君.双柏散外敷加红外线照射治疗慢性盆腔炎的疗效观察[J].药物与护理,2005,11(13)：1044-1045
[83]陈宝玉,林永红.双柏软膏与热敷散治疗输液后渗出疗效比较.新中医,1995,27(11)：62
[84]李永浩.双柏散外敷治疗肝癌疼痛疗效观察[J].中医外治杂志,2004,13(3)：26-27
[85]陈泰华,陈玉琨.用双柏散外敷治疗癌性疼痛57例[J].新中医,2003,35(11)：59-60
[2]Goldstein FJ. Adjuncts to opioid therapy[J].J Am Osteopath Assoc,2002,102 (9):S152S21.
[3]周之毅,刘慧.癌性疼痛的中医药质量进展[J].辽宁中医杂志,2007,34(4)：534-536.
[4]白桦,李忠,张雅月.中药外用缓解癌性疼痛的研究现状与思路[J].中医外治志,2009,18(1)：46-48.
[5]Parkin DM,Bray F, Ferlay J,et al.Global cancer statistics[J].CA Cancer J Clin,2005,55(2):74-108.
[6]Summerfield JA. Virus hepatitis update[J]. J R Coll Physicians Lond,2000,34(4): 381-385
[7]丁凯,周华富,冯志强.原发性肝癌的病因研究与进展[J].中国新医学论坛,2008,8(8)：21-24
[8]Hitzfeld BC, Hoger SJ, Dietrich DR. cyanobacterial toxins:removal during drinking water treatment and haman risk assessment [J]. Environ Health Perspect,2000,108(SI): 113-122
[9]董先杰,邵英梅.原发性肝癌的治疗进展,现代肿瘤医学,2009,17(09)：1814-1817
[10]Josep M, Llovet, Josep Fuster, et al. The barcelona approach:diagnosis, stag ing, and treatment of hepatocellular carcinoma[J]. Liver Transpl,2004,10:S115 S120.
[11]Lencioni R, Cioni D, Crocetti L, et a 1. Early stage hepatocellular carcinoma in patients with cir rhosis:long-term results of percutaneo us image guided radio frequency ablation[J]. Radiolo gy,2005,234(3):961-967.
[12]尹光忍,何世举.原发性肝癌的诊断及治疗现状[J].检验医学与临床2010,7(17)：1900-1901
[13]张亦琳,朱建平,叶军.肝癌的治疗方法[J].健康博览,2010,(11)：12—13.
[14]Boige V, Barbare JC, Rosmorduc 0, et al. Use of sorafenib (Nexav ar) in the t reatment of hepatocel lular carcinoma:PRODIGE AFEF recommendations [J]. Gastro errterol Clin Biol,2008,32(1 Pt 1):3-7
[15]周际吕.实用肿瘤内科学[M].北京：人民卫生出版社,2003.
[16]Honore P, Rogers SD, S chweiM J, et al M urine models of inflammatory, neuropath ic and cancer pain each generates a uniqueset of neu roch em ical ch anges in the spinal cord and sensory neurons[J]. N euroscience,2000,98(3):585-598.
[17]张瑛,韩济生,王韵.癌症痛的神经生物学机制研究进展[J].生理科学进展,2004,35(3)：224-228.
[18]Sabino MA, Luger NM, Mach DB, et al Different tumors in bone each give rise to a distinct pattern of skeletal destruction, bone cancer-related pain b ehaviors and neurochem ical changes in the centralnorvous system [J]. Int J Cancer,2003,104 (5):550 558.
[19]Manthyh PW, Clohisy DR, Kohzenbu rg M, et a.l Molecular mechanisms of cancer pain [J]. Nature Rev (Cancer),2002,2(3):201-209.
[20]王妙苗.癌瘙的发生机制及其相关药物治疗的研究现状[J].临床肿瘤学杂志,2011,16(7)：662-666
[21]Poon RT, Fan ST, Ng 10, et al. Difference risk factors and prognosis for early and late intrahepatic recurrence after resection of hepatocellular carcinoma[J]. Cancer,2000,83(3):500-507.
[22]程乐,钟进才.阿片类药物应用于中重度癌瘙治疗的研究进展[R].广西医学,2009,31(5)：742-745.
[23]徐学庆,刘雨桃,译.吗啡的新作用抑癌作用及其机制[J].日本医学介绍,2000,21(11)：522-523.
[24]Goldstein FJ. Adjuncts to opioid therapy [J].J Am Osteopath Assoc,2002,102(9):S152S21.
[25]周之毅,刘慧.癌性疼痛的中医药质量进展[J].辽宁中医杂志,2007,34(4)：534-536.
[26]刘端祺.“三阶梯”止痛原则临床实践20年[J].医学与哲学(临床决策论坛版),2007,28(10)：10-18
[27]周岱翰.临床中医肿瘤学[M].北京：人民卫生出版社,2003,1：175
[28]吴勉华.周仲瑛教授从癌毒辨治恶性肿瘤用药分析[N].南京中医药大学学报2010,26(4)
[29]赵磊.周维顺治疗肝癌经验[J].山西中医.2010,26,(12)：9-12
[30]逯敏.刘伟胜教授治疗肿瘤学术思想探讨[J].中国中医急症.2010,19(7)：1162-1163
[31]袁海英.陈培丰教授治疗肝癌经验[J].浙江中西医结合杂志.2009,19(12)
[32]吕书勤.浅析肝癌与湿[J].天津中医药,2004,21(2)
[33]吴良村,成文武,郭勇,等.中西医治疗原发性肝癌经验[J].浙江中医学院学报,2000,(4)：5
[34]苏全胜,薛利军,等.复方苦参注射液治疗老年晚期癌症患者疼痛临床体会[J]中国中医急症,2009,18(10)：1692
[35]刘安,魏静,谭镇岳.复方苦参注射液缓解癌痛的临床与实验研究[J].吉林中医药,2005,25(6)：54
[36]司富春,李建省.中医治疗癌痛证型方药分析[N].中医学报,2010-12,25(4)：
[37]王国平.清营汤加味治疗癌性疼痛68例观察[J].山西中医,1992,8(1)：25.
[38]林胜友.马钱子治疗癌性疼痛35例[J].辽宁中医杂志,1993,20(2)：41-42
[39]刘昭坤.芍药甘草汤为主治疗癌症晚期疼痛40例.新中医,1997,29(1)：29-33
[40]陈长怀,孙桂芝,唐文秀,等.桂参止痛合剂治疗癌症疼痛临床观察[J].中国新药杂志,2000,9(3)：196-200
[41]郑少翰,卓建腾.益气化瘀解毒方防治癌性疼瘙32例[J].福建中医药,2005,36(6)10-11.
[42]魏强,陈树泉,王兆香,等.酸味三君子方治疗癌性疼瘙临床观察[J].河南中医,2005,25(12)：34-34.
[43]周岱翰.临床中医肿瘤学[M].北京：人民卫生出版社,2003：70.
[44]李忠.浅述癌性疼瘙的中医论治八大法[J]. 中国临床医生,2000,28(9)：40-42.
[45]陈世伟,张利民.肿瘤中西医综合治疗.北京：人民卫生出版社,2001.195
[46]刘延庆.癌性疼痛的中医药治疗[J].江苏中医药,2008.40(9)：9.
[47]汀德家.针刺治疗癌性疼痛32例疗效观察[J].实用中医内科杂志,2007,21(9)：96-97
[48]陈仲杰,郭宇鹏. 以瘙为腧针刺治疗癌性疼痛疗效观察[J]. 中国针灸,2008,28(4)：251-252.
[49]殷常春.蟾皮止痛膏治疗癌性疼痛28例[J].中医外治杂志,2000,9(6)：10-11
[50]龚金兴,尤建良.消癥止痛膏的研制及临床疗效观察[J].中药材,2002,25(8)：611612
[51]胡怀强,李杰.癌痛膏外敷治疗肝癌疼痛46例[J].中医外治杂志,1998,7(2)：18.
[52]孙琛,唐由君.中医药外治肝癌疼痛的研究进展[J].中医外治杂志,2008,17(1)：44-46.
[53]赵玉香,赵玉玲,胡遵荣.疏络膏穴位外敷缓解癌症疼痛的临床研究[J].中医外治杂志,2003,12(2)：1
[54]韩子敏,刘兴明.中药穴区外敷治疗癌痛44例[J].中日友好医院学报,1998,12
[55]徐钧.癌瘙酊外用治疗晚期肝癌疼痛临床观察[J].现代中西医结合杂志,1999,8(7)：1076.
[56]李佑民,刘组发.冰红酊剂外用治疗肝癌疼痛42例[J].中西医结合肝病杂志,1999,9(1)：44.
[57]李敏,马岩.癌痛灵贴膏外用治疗胰腺癌癌性疼痛的疗效观察[J].华西医学,2010,25(3)：604-606
[58]李园.祛痛喷雾酊治疗癌性疼痛的临床与实验研究[J].中医杂志,1999,40(10)：609.
[59]杨劫,寇胜玲,旋志刚.元麝止痛液的制备及治疗癌性疼痛的疗效观察[J].中成药,2005,27(2)：243
[60]白桦,李忠,张雅月.中药外用缓解癌性疼痛的研究现状与思路[J].中医外治杂志,2009,18(1)： 46-48
[61]王凯,范晓鹏,林亚杰.外治法治疗肝癌癌性疼痛临床观察[J].上海中医药杂志2002,36(7)：19-20
[62]刘安,魏静,谭镇岳.中药贴脐缓解癌痛的临床与实验研究[J].云南中医中药杂志,2005,26(2)： 25-26
[63]吴迪,冯肖卿,李卫东.四黄散外敷治疗原发性肝癌疼痛临床观察[J].中材药,2010,3(37)：1197-1199.
[64]李永浩.双柏散外敷治疗肝癌疼痛疗效观察[J].中医外治杂志,2004,13(3)：26.
[65]孙韩静.冰黄寄奴散外敷治疗癌性疼痛35例疗效观察[J].新中医,2007,39(2)：84-85.
[66]王鹏,吴勉华.中医外治法在癌性疼痛中应用概述[J].实用中医内科杂志,2006,20(6)：589.
[67]郑玉玲.癌痛中医外治概况[J].光明中医杂志,1994,(1)：41-45
[68]曹海涛,张彩,徐燎宇.何裕民中医外治法治疗肿瘤经验[J].中医文献杂志,2006,(1)：36-37.
[69]杨瑶瑶,鲍艳举,花宝金.中医外治法治疗癌性疼瘙的药物分析[J].中国中医药信息杂志,2010,17(5)：94-95.
[70]邓宏,吴万垠,柴小垠.刘伟胜教授辨治癌痛经验介绍[J].新中医,2009,41(3)：15-16.
[71]何子强.肝癌疼瘙中医外治法[J].中医外治杂志,1995,(1)：27-29
[72]梁学政,吴昭璇.双柏散制剂的研究及临床应用进展.中国药业,2003,12(7)：77-78
[73]欧阳伟珊,刘东辉,魏刚.双柏散各单味药有效部位抗炎镇瘙祛瘀作用研究[J].中药药理与临床,2011,27(2)：118-121
[74]魏刚,方永奇,刘东辉.双柏散治疗作用的化学物质基础探讨[J].中药新药与临床药理,2002,13(5)：330-331
[75]方永奇,谢沙,黄可儿,等.双柏散抗炎作用及其有效部位的研究[J].广州中医学院学报,1991,8(1)：22-23
[76]吴启瑞,方永奇,黄可儿,等.双柏炎痛喷雾剂抗炎镇痛作用研究[J].中国实验方剂学杂志,1999,5(5)：49-50
[77庄洪,岑泽波,袁浩,等.外用双柏散浸剂治疗急性软组织损伤的实验研究[J].中医止骨,1992,4(2)：4-5
[78]李惠东,黄玫.双柏散在治疗创伤性肋骨骨折中的作用[J].广州医学,1998,29(4)：54-56
[79]胡继功,谢贵四.双柏散治疗骨折后软组织肿胀的疗效观察[J]贵阳中医学院学报,2011,33(4)：51-52
[80]卓晓英,罗丽英,龚博慎.双柏散外敷治疗急性软组织损伤1681例的临床观察[J].中国现代医学杂志,2006,16(5)：2389-2390
[81]郑泽棠.双柏散在外科中的应用.新中医,1992,24(4)：29
[82]张菲辉,李惠君.双柏散外敷加红外线照射治疗慢性盆腔炎的疗效观察[J].药物与护理,2005,11(13)：1044-1045
[83]陈宝玉,林永红.双柏软膏与热敷散治疗输液后渗出疗效比较.新中医,1995,27(11)：62
[84]李永浩.双柏散外敷治疗肝癌疼痛疗效观察[J].中医外治杂志,2004,13(3)：26-27
[85]陈泰华,陈玉琨.用双柏散外敷治疗癌性疼痛57例[J].新中医,2003,35(11)：59-60